Current HIV/AIDS reports · 2026
HSV, HIV, and Pregnancy: Epidemiology, Viral Interactions, Management, and Prevention.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Halani Sheliza, Yudin Mark H, Tan Darrell H S
Аннотация
PURPOSE OF REVIEW: We summarize the epidemiology, biology, management and prevention of HSV-2 and HIV in pregnancy.
RECENT FINDINGS: The seroprevalence of HSV-2 is higher in people living with HIV than in HIV-negative people, and 75% of women with recurrent genital herpes may have a recurrence during pregnancy. Those with a history of recurrent genital HSV infection should be offered acyclovir/valacyclovir at 36 weeks gestation to decrease need for C-section. The most important intervention for reducing HIV vertical transmission is maternal antiretroviral therapy (ART) to suppress HIV replication. Maternal ART also reduces HSV-2 cervicovaginal shedding and thus, HSV-2 vertical transmission. HSV-2 viral shedding is incompletely suppressed with acyclovir/valacyclovir, and newer drugs such as the helicase-primase inhibitors show promise but have not been studied in pregnancy. Safe options also exist for preventing HIV acquisition in pregnancy but remain in development for HSV-2. Safe, effective HSV-2/HIV management strategies exist in pregnancy.
RECENT FINDINGS: The seroprevalence of HSV-2 is higher in people living with HIV than in HIV-negative people, and 75% of women with recurrent genital herpes may have a recurrence during pregnancy. Those with a history of recurrent genital HSV infection should be offered acyclovir/valacyclovir at 36 weeks gestation to decrease need for C-section. The most important intervention for reducing HIV vertical transmission is maternal antiretroviral therapy (ART) to suppress HIV replication. Maternal ART also reduces HSV-2 cervicovaginal shedding and thus, HSV-2 vertical transmission. HSV-2 viral shedding is incompletely suppressed with acyclovir/valacyclovir, and newer drugs such as the helicase-primase inhibitors show promise but have not been studied in pregnancy. Safe options also exist for preventing HIV acquisition in pregnancy but remain in development for HSV-2. Safe, effective HSV-2/HIV management strategies exist in pregnancy.